Active ingredientFlumatinibCat. No. P-F076-001CAS 895519-90-1Family · Pharmaceutical analytical standards
Flumatinib
A second-generation BCR-ABL tyrosine kinase inhibitor, approved in China in late 2019 for adults with Philadelphia chromosome-positive chronic myeloid leukaemia in the chronic phase. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It is a derivative of imatinib: compared with its parent drug, one of its benzene rings is replaced by a pyridine and a trifluoromethyl group is added, which make additional contacts with the target kinase.
Go to the active ingredient →Active ingredientFlumatinibCat. No. P-F076-001CAS 895519-90-1
Active ingredientFlumatinib MesylateCat. No. P-F076-002CAS 895519-91-2
Isotopically labelledFlumatinib Impurity 1-d3Cat. No. P-F076-004
Isotopically labelledFlumatinib Mesylate-13C, d3Cat. No. P-F076-005
Isotopically labelledFlumatinib Mesylate-d8Cat. No. P-F076-007
Isotopically labelledFlumatinib-d3Cat. No. P-F076-008
Isotopically labelledN-Desmethyl Flumatinib-d8Cat. No. P-F076-009
NitrosamineN-Nitroso FlumatinibCat. No. P-F076-010
Impurity3-(Trifluoromethyl)benzoic acidCat. No. P-F076-011CAS 454-92-2
ImpurityN-Desmethyl FlumatinibCat. No. P-F076-012CAS 1312165-54-0
ImpurityFlumatinib ImpurityCat. No. P-F076-013CAS 859027-02-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.